B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
作者信息
Shaw T, Quan J, Totoritis M C
机构信息
Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK.
出版信息
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii55-9. doi: 10.1136/ard.62.suppl_2.ii55.
Abstract
摘要
相似文献
1
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.类风湿关节炎的B细胞疗法：利妥昔单抗（抗CD20）的应用经验
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii55-9. doi: 10.1136/ard.62.suppl_2.ii55.
2
[Anti-CD20 antibody therapy for inflammatory immune diseases].[抗CD20抗体疗法用于炎症性免疫疾病]
Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1801-6. doi: 10.2169/naika.95.1801.
3
[Rituximab treatment of rheumatoid arthritis: new evidence].[利妥昔单抗治疗类风湿关节炎：新证据]
Ter Arkh. 2009;81(6):82-91.
4
Long term treatment of rheumatoid arthritis with rituximab.利妥昔单抗用于类风湿关节炎的长期治疗。
Autoimmun Rev. 2009 Jun;8(7):591-4. doi: 10.1016/j.autrev.2009.02.008. Epub 2009 Feb 11.
5
[Targeting CD20 in rheumatoid arthritis].[靶向类风湿关节炎中的CD20]
Nihon Rinsho. 2007 Jul;65(7):1243-9.
6
B-cell: a logical target for treatment of rheumatoid arthritis.B细胞：类风湿关节炎治疗的合理靶点。
Clin Exp Rheumatol. 2007 Mar-Apr;25(2):318-28.
7
B cells, be gone--B-cell depletion in the treatment of rheumatoid arthritis.B细胞，消失吧——类风湿关节炎治疗中的B细胞清除疗法
N Engl J Med. 2004 Jun 17;350(25):2546-8. doi: 10.1056/NEJMp048114.
8
[B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].[类风湿关节炎中使用抗CD20抗体的B细胞耗竭疗法]
Clin Calcium. 2007 Apr;17(4):569-76.
9
Rituximab: a new therapeutic alternative in rheumatoid arthritis.利妥昔单抗：类风湿关节炎的一种新的治疗选择。
Joint Bone Spine. 2008 Oct;75(5):526-32. doi: 10.1016/j.jbspin.2008.02.009. Epub 2008 Jun 20.
10
[Recent topics on new biological agents for treatment of rheumatoid arthritis].[类风湿关节炎治疗新型生物制剂的近期研究主题]
Nihon Naika Gakkai Zasshi. 2008 Oct 10;97(10):2418-23. doi: 10.2169/naika.97.2418.
引用本文的文献
1
Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis.基于网络的现代药物靶点与甲氨蝶呤新组合用于类风湿关节炎基于反应的治疗的计算机模拟分析
J Pers Med. 2023 Oct 29;13(11):1550. doi: 10.3390/jpm13111550.
2
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.调整 CAR：修饰嵌合抗原受体 (CAR) T 细胞活性以提高安全性、疗效和灵活性的最新进展。
J Transl Med. 2023 Mar 15;21(1):197. doi: 10.1186/s12967-023-04041-6.
3
Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage.类风湿关节炎血清抗体针对瓜氨酸化的 II 型胶原，可与关节软骨结合。
Arthritis Res Ther. 2022 Nov 22;24(1):257. doi: 10.1186/s13075-022-02945-0.
4
Applying differential network analysis to longitudinal gene expression in response to perturbations.将差异网络分析应用于响应扰动的纵向基因表达研究。
Front Genet. 2022 Oct 17;13:1026487. doi: 10.3389/fgene.2022.1026487. eCollection 2022.
5
Methotrexate-loaded nanoparticles ameliorate experimental model of autoimmune arthritis by regulating the balance of interleukin-17-producing T cells and regulatory T cells.载甲氨蝶呤纳米粒通过调节白介素-17 产生 T 细胞和调节性 T 细胞的平衡改善实验性自身免疫性关节炎。
J Transl Med. 2022 Feb 11;20(1):85. doi: 10.1186/s12967-022-03267-0.
6
Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models.恢复促炎细胞因子与抗炎细胞因子之间的平衡在类风湿关节炎治疗中的作用：来自动物模型的新见解
Biomedicines. 2021 Dec 26;10(1):44. doi: 10.3390/biomedicines10010044.
7
Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis.利妥昔单抗治疗难治性重症肌无力及其在抗肌肉特异性激酶（MuSK）阳性和抗乙酰胆碱受体（AChR）阳性重症肌无力中疗效的变异性
Cureus. 2021 Nov 9;13(11):e19416. doi: 10.7759/cureus.19416. eCollection 2021 Nov.
8
The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.类风湿关节炎的治疗前景：现状与未来方向
Front Pharmacol. 2021 May 28;12:680043. doi: 10.3389/fphar.2021.680043. eCollection 2021.
9
Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature.含利妥昔单抗化疗治疗原发性中枢神经系统淋巴瘤期间发生的间质性肺炎：一例报告并文献复习
Chin Neurosurg J. 2018 Jan 8;4:1. doi: 10.1186/s41016-017-0106-3. eCollection 2018.
10
Etanercept Inhibits B Cell Differentiation by Regulating TNFRII/TRAF2/NF-B Signaling Pathway in Rheumatoid Arthritis.依那西普通过调节类风湿关节炎中的TNFRII/TRAF2/NF-κB信号通路抑制B细胞分化。
Front Pharmacol. 2020 May 12;11:676. doi: 10.3389/fphar.2020.00676. eCollection 2020.
本文引用的文献
1
The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets.B细胞在类风湿关节炎中的作用：机制与治疗靶点
Curr Opin Rheumatol. 2003 May;15(3):246-52. doi: 10.1097/00002281-200305000-00011.
2
Treatment of IgM antibody associated polyneuropathies using rituximab.使用利妥昔单抗治疗IgM抗体相关的多发性神经病。
J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9. doi: 10.1136/jnnp.74.4.485.
3
Clonal analysis of B cells in the synovial membrane of patients with rheumatoid arthritis.类风湿性关节炎患者滑膜中B细胞的克隆分析。
Scand J Rheumatol. 2003;32(1):12-8. doi: 10.1080/03009740310000346.
4
Efficacy and safety of rituximab in type II mixed cryoglobulinemia.利妥昔单抗治疗II型混合性冷球蛋白血症的疗效与安全性。
Blood. 2003 May 15;101(10):3827-34. doi: 10.1182/blood-2002-09-2856. Epub 2003 Jan 30.
5
An open study of B lymphocyte depletion in systemic lupus erythematosus.系统性红斑狼疮中B淋巴细胞耗竭的开放性研究。
Arthritis Rheum. 2002 Oct;46(10):2673-7. doi: 10.1002/art.10541.
6
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.利妥昔单抗作为惰性非霍奇金淋巴瘤患者的一线及维持治疗药物
J Clin Oncol. 2002 Oct 15;20(20):4261-7. doi: 10.1200/JCO.2002.08.674.
7
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.22例接受B淋巴细胞清除治疗的类风湿关节炎患者的临床结局
Ann Rheum Dis. 2002 Oct;61(10):883-8. doi: 10.1136/ard.61.10.883.
8
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.选择性B细胞阻断在类风湿关节炎治疗中的疗效：B细胞致病作用的证据
Arthritis Rheum. 2002 Aug;46(8):2029-33. doi: 10.1002/art.10467.
9
B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.类风湿关节炎及其他自身免疫性疾病中的B淋巴细胞清除疗法。
Biochem Soc Trans. 2002 Aug;30(4):824-8. doi: 10.1042/bst0300824.
10
Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis.类风湿关节炎患者滑膜腔中存在一群增殖反应有缺陷的CD20+、CD38- B淋巴细胞。
Arthritis Rheum. 2001 Sep;44(9):2029-37. doi: 10.1002/1529-0131(200109)44:9<2029::AID-ART352>3.0.CO;2-2.
Zotero 插件